Abpro Corporation (ABP) 주식 분석

회사 개요

Abpro Corporation, abbreviated as ABP, is a biotechnology firm that specializes in developing novel antibody constructs primarily for applications in immuno-oncology and ophthalmology. The company operates within the broader Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on high-risk, high-reward research and development aimed at advancing medical treatments. The entity employs a small workforce of 6 individuals to execute its strategic platform initiatives, including the DiversImmune discovery platform and MultiM technologies. With a market capitalization of $1.42M and reported annual revenue of $0, the company represents a micro-cap entity with negligible market presence. These valuation figures indicate that the firm is in an early-stage development phase where financial metrics are driven by operational expenses and R&D investments rather than commercial sales, reflecting a typical profile for a pre-revenue biotechnology company seeking to validate its proprietary assets before entering the commercial market.

재무 건전성

The financial statements for the trailing twelve months reveal a revenue of $0, a net income of $-22,040,000, and an EBITDA of $-9,301,000. The substantial gap between zero revenue and a negative net income exceeding $22 million highlights a cost structure dominated entirely by operating expenses, likely consisting of research and development costs, personnel salaries, and general administrative overhead. Despite the significant net loss, the company reports a free cash flow of $6.37M, which suggests a positive cash conversion cycle or the utilization of prior cash reserves to fund current operations without immediate external financing. The gross margin stands at 0.0%, the operating margin is 0.0%, and the profit margin is also 0.0%, indicating that the company has not yet achieved profitability from its core business activities due to the absence of sales revenue. On the balance sheet, the company holds $328,000 in cash against $147,000 in debt, while the debt-to-equity ratio is listed as N/A due to the lack of positive equity. The current ratio is recorded at 0.07, a figure that indicates severe short-term liquidity constraints as current liabilities significantly exceed current assets. Return on Equity is N/A, while Return on Assets stands at -229.6%, a metric that reveals that management is currently destroying asset value on a per-dollar basis relative to the total asset base.

밸류에이션 평가

The trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that traditional earnings-based valuation methods are inapplicable given the company's lack of profitability and earnings history. The price-to-book ratio is recorded at -0.09, a negative figure that indicates the market capitalization is less than the book value of shareholders' equity, often seen in distressed or pre-revenue entities where assets may not be valued at their accounting book value. The price-to-sales ratio is listed as inf (infinity) because the company has zero revenue, meaning the market assigns a valuation without any sales base to compare against. Additionally, the EV/EBITDA multiple is -0.19, which serves as an alternative valuation metric that further reflects the company's negative earnings position rather than a standard valuation multiple. The stock has traded between a 52-week high of $18.03 and a 52-week low of $0.11. Based on the provided data, the current trading price sits within this wide range, though the specific percentage relative to the current price is not calculable without the real-time quote, but the range demonstrates extreme price volatility. The beta value is -0.00, a statistically anomalous figure for an equity security that technically implies zero correlation with or movement in the broader market, suggesting the stock price is driven almost exclusively by idiosyncratic factors rather than general market trends.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A due to the absence of prior period revenue data and the current lack of earnings. Consequently, there is no historical growth trajectory to analyze regarding whether earnings are growing faster or slower than revenue, as the company has not yet generated commercial income. As a non-dividend payer, the company does not distribute any cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This indicates that the company retains all available cash, or rather, relies on its cash reserves and potential future funding to reinvest into its growth initiatives rather than providing income to investors. The overall growth and income profile for Abpro Corporation is characterized by a complete absence of commercial revenue, negative earnings, and no dividend payments, positioning the asset purely as a speculative investment based on future potential rather than current financial performance or income generation.